This white paper provides a summary of a scientific proposal presented at a Cardiac Safety
Research Consortium/Health and Environmental Sciences Institute/Food and Drug …

Engineered heart tissue has emerged as a personalized platform for drug screening. With
the advent of induced pluripotent stem cell (iPSC) technology, patient-specific stem cells can …

Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patients.
The mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood …

Background—Drug-induced arrhythmia is one of the most common causes of drug
development failure and withdrawal from market. This study tested whether human induced …

The application of tissue-engineering approaches to human induced pluripotent stem (hiPS)
cells enables the development of physiologically relevant human tissue models for in vitro …

Transplantation of engineered tissue patches containing either progenitor cells or
cardiomyocytes for cardiac repair is emerging as an exciting treatment option for patients …

Billions of US dollars are invested every year by the pharmaceutical industry in drug
development, with the aim of introducing new drugs that are effective and have minimal side …

An in vitro drug-induced cardiotoxicity assay is a critical step in drug discovery for clinical
use. The use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) …

Organ dysfunction is a major cause of morbidity and mortality. Transplantation is typically the
only definitive cure, challenged by the lack of sufficient donor organs. Tissue engineering …

Human pluripotent stem cells (hPSCs) offer a multifaceted platform to study cardiac
developmental biology, understand disease mechanisms, and develop novel therapies …